Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

A Randomized, Double-blind, Active Controlled, Multi-center, Phase 1 Study to Investigate the Safety of MEDITOXIN® in Female Subjects With Idiopathic Overactive Bladder

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

Inclusion Criteria:

• Female aged more than 20 years
• Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening

Exclusion Criteria:

- Patient not appropriate for participating in this study according to the investigator's opinion